The epidemiology of mumps in southern Alberta 1980-1982
- PMID: 2505612
- DOI: 10.1093/oxfordjournals.aje.a115395
The epidemiology of mumps in southern Alberta 1980-1982
Abstract
The full spectrum of mumps in Southern Alberta was studied over the years 1980-1982. In the community, a random sample of 3,497 children was tested for prevalence of immunity to mumps. The 1,816 who were not immune were retested after one year. The incidence of new immunity was 16.5%. Most seroconverters had no illness suggestive of mumps. History of previous mumps or immunization were found to be unreliable predictors of serologic immune status. In the family study, information was obtained on 342 cases diagnosed as mumps by family physician recorders. The overall complication rate was 10.8% and the secondary attack rate within families was 11.7%. Hospital records of all 25 patients admitted in Calgary with mumps during the same period were analyzed. Estimated costs of unopposed mumps over 20 years compared with the estimated costs of vaccination showed that a vaccination program could give a benefit-cost ratio between 6.4 and 247. These studies show that mumps is a mild disease with relatively few serious complications or sequelae. Even so, there would be definite medical and economic benefit with immunization. A low-cost addition of mumps vaccine to the immunization program would be justified.
Similar articles
-
Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.Vaccine. 2013 May 31;31(24):2661-6. doi: 10.1016/j.vaccine.2013.04.014. Epub 2013 Apr 17. Vaccine. 2013. PMID: 23602654
-
Measles and mumps immunization: benefit versus risk factors.Dev Biol Stand. 1979;43:253-7. Dev Biol Stand. 1979. PMID: 520672
-
Saliva antibody testing and vaccination in a mumps outbreak.CDR (Lond Engl Rev). 1991 Aug 16;1(9):R96-8. CDR (Lond Engl Rev). 1991. PMID: 1669793
-
[Wide-spread inflammation of the parotid glands (mumps): an underestimated disease. II. Development, use, efficacy and safety of mumps vaccines].Przegl Epidemiol. 1998;52(4):401-12. Przegl Epidemiol. 1998. PMID: 10321084 Review. Polish.
-
[Mumps epidemiology--worldwide].Soz Praventivmed. 1995;40(2):93-101. doi: 10.1007/BF01360323. Soz Praventivmed. 1995. PMID: 7747526 Review. German.
Cited by
-
Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis.Clin Vaccine Immunol. 2011 Jan;18(1):35-42. doi: 10.1128/CVI.00284-10. Epub 2010 Nov 3. Clin Vaccine Immunol. 2011. PMID: 21047998 Free PMC article.
-
Chinese medicinal herbs for mumps.Cochrane Database Syst Rev. 2015 Apr 18;2015(4):CD008578. doi: 10.1002/14651858.CD008578.pub3. Cochrane Database Syst Rev. 2015. PMID: 25887348 Free PMC article.
-
Atypical Mumps; are We Heading Towards an Outbreak?Indian J Otolaryngol Head Neck Surg. 2024 Oct;76(5):4138-4145. doi: 10.1007/s12070-024-04802-9. Epub 2024 Jun 20. Indian J Otolaryngol Head Neck Surg. 2024. PMID: 39376365
-
Molecular biology, pathogenesis and pathology of mumps virus.J Pathol. 2015 Jan;235(2):242-52. doi: 10.1002/path.4445. J Pathol. 2015. PMID: 25229387 Free PMC article. Review.
-
Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.Pediatr Infect Dis J. 2013 Apr;32(4):374-80. doi: 10.1097/INF.0b013e318279f593. Pediatr Infect Dis J. 2013. PMID: 23099425 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical